Definitive Contract 75N91019C00028
Award Date
9/16/19
Potential Completion Date
9/15/21
Potential Value
$355K
Federal Agency
National Cancer Institute
Awardee
Byomass Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Sudbury, MA 01776, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>
This is a $400,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Biosensics LLC, a small business located in Newtonville, Massachusetts. The contract is for the development of an automated screening platform to enable early identification of malnutrition in cancer patients. This contract award is part of the FY24 SBIR solicitation, which covers a variety of research topics...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This definitive contract for $1,345,018 was awarded by the National Cancer Institute, a component of the Department of Health and Human Services, to Biomarker Strategies LLC of Derwood, Maryland. The contract is associated with Small Business Innovation Research Program Phase II funding and supports the development of a novel predictive test for response to combination immunotherapies for patients with non-small cell lung cancer. The firm fixed price contract has a completion date of August...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>
This is a federal contract award by the National Cancer Institute (NCI), a civilian agency, to Sophic Systems Alliance Inc., a small business veteran-owned contractor. The contract is for a System to Analyze and Support Biomarker Research and Development Strategies under the Small Business Innovation Research (SBIR) Program Phase II. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $745,999.90 and a period of performance ending on August...
<p>This is a $199,969 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Accelerated Medical Diagnostics, Inc. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type with a completion date of September 30, 2016. As an SBIR Phase I award, this contract supports early-stage research and development activities.</p>
This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>